Page last updated: 2024-11-13

bephenium hydroxynaphthoate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

bephenium hydroxynaphthoate: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID54678490
CHEMBL ID1673148
SCHEMBL ID466996
MeSH IDM0049465

Synonyms (63)

Synonym
n,n-dimethyl-n-(phenylmethyl)-2-(phenyloxy)ethanaminium 3-hydroxynaphthalene-2-carboxylate
3818-50-6
bephenium hydroxynaphthoate
HMS2093D12
naphthammonum
bephene oxinaphtoate
naftamon
befen
bephenium 3-hydroxy-2-naphthoate
nsc-759245
debefenium
befeniol
frantin
alcopara
naphtamon
bephenamine hydroxynaphthoate
naphtamone
CHEMBL1673148
fedal-uncin
lecibis
bephenii hydroxynaphthoas
bephenium embonate
HMS2097L14
hidroxinaftoato de befenio
47ru9546dx ,
alcopar
benzyldimethyl(2-phenoxyethyl)ammonium-3-hydroxy-2-naphthoate
benzyldimethyl(2-phenoxyethyl)ammonium 3-hydroxy-2-naphthoate (1:1)
bephenii hydroxynaphthoas [inn-latin]
unii-47ru9546dx
befenium
hidroxinaftoato de befenio [inn-spanish]
benzenemethanaminium, n,n-dimethyl-n-(2-phenoxyethyl)-, salt with 3-hydroxy-2-naphthalenecarboxylic acid (1:1)
hydorxynaphtoate de bephenium [inn-french]
hydorxynaphtoate de bephenium
bephenium hydroxynaphthoate [usp:inn:ban]
einecs 223-306-8
nsc 759245
naphthammon
bephenium hydroxynaphthoate [mi]
bephenii hydroxynaphthoas [who-ip latin]
bephenium hydroxynaphthoate [mart.]
bephenium hydroxynaphthoate [who-dd]
bephenium hydroxynaphthoate [who-ip]
bephenium hydroxynaphthoate [inn]
CCG-213548
CS-3886
SCHEMBL466996
bepheniumhydroxynaphthoate
bephenium (hydroxynaphthoate)
HY-12639A
DTXSID8022662
AKOS026749857
bephenium hydroxynaphthoate, analytical standard
bephenium hydroxynaphthoate, united states pharmacopeia (usp) reference standard
HMS3714L14
SW199402-2
FT-0712569
n-benzyl-n,n-dimethyl-2-phenoxyethanaminium 3-hydroxy-2-naphthoate
E78468
BS-49247
benzyl-dimethyl-(2-phenoxyethyl)azanium;3-carboxynaphthalen-2-olate
benzenemethanaminium, n,n-dimethyl-n-(2-phenoxyethyl)-,

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"Hamsters infected with laboratory-adapted preadult Necator americanus were dosed with 6 reference anthelmintics."( Response of preadult Necator americanus to some known anthelmintics in hamsters.
Bose, S; Deb, BN; Dhage, KR; Rajasekariah, GR, 1986
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID574281Antiparasitic activity against Ancylostoma caninum isolate NT assessed as compound concentration required to inhibit parasitic contraction by larval motility assay2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Phenotypic characterization of two Ancylostoma caninum isolates with different susceptibilities to the anthelmintic pyrantel.
AID574278Antiparasitic activity against Ancylostoma caninum isolate NT assessed as compound concentration required to inhibit parasitic contraction by larval arrested morphology assay2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Phenotypic characterization of two Ancylostoma caninum isolates with different susceptibilities to the anthelmintic pyrantel.
AID574288Ratio of EC50 for Ancylostoma caninum isolate PR to IC50 for Ancylostoma caninum isolate NT by by force transduction assay2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Phenotypic characterization of two Ancylostoma caninum isolates with different susceptibilities to the anthelmintic pyrantel.
AID574280Ratio of IC50 for Ancylostoma caninum isolate NT to IC50 for Ancylostoma caninum isolate PR by larval arrested morphology assay2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Phenotypic characterization of two Ancylostoma caninum isolates with different susceptibilities to the anthelmintic pyrantel.
AID574283Ratio of IC50 for Ancylostoma caninum isolate NT to IC50 for Ancylostoma caninum isolate PR by larval motility assay2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Phenotypic characterization of two Ancylostoma caninum isolates with different susceptibilities to the anthelmintic pyrantel.
AID574279Antiparasitic activity against Ancylostoma caninum isolate PR assessed as compound concentration required to inhibit parasitic contraction by larval arrested morphology assay2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Phenotypic characterization of two Ancylostoma caninum isolates with different susceptibilities to the anthelmintic pyrantel.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID574282Antiparasitic activity against Ancylostoma caninum isolate PR assessed as compound concentration required to inhibit parasitic contraction by larval motility assay2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Phenotypic characterization of two Ancylostoma caninum isolates with different susceptibilities to the anthelmintic pyrantel.
AID574287Antiparasitic activity against Ancylostoma caninum isolate PR assessed as concentration of drug required to cause a force of contraction half that of the KCl-induced maximal contraction by force transduction assay2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Phenotypic characterization of two Ancylostoma caninum isolates with different susceptibilities to the anthelmintic pyrantel.
AID574286Antiparasitic activity against Ancylostoma caninum isolate NT assessed as concentration of drug required to cause a force of contraction half that of the KCl-induced maximal contraction by force transduction assay2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Phenotypic characterization of two Ancylostoma caninum isolates with different susceptibilities to the anthelmintic pyrantel.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (39)

TimeframeStudies, This Drug (%)All Drugs %
pre-199037 (94.87)18.7374
1990's0 (0.00)18.2507
2000's2 (5.13)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.75

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.75 (24.57)
Research Supply Index4.06 (2.92)
Research Growth Index4.14 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.75)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.79%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (1.79%)4.05%
Observational0 (0.00%)0.25%
Other54 (96.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]